艾普拉唑、铋剂联合抗生素不同疗程治疗幽门螺杆菌相关性慢性胃炎的效果比较

Abstract
Figure/Table
References (17)
Related Citation (13)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the curative effect of one week therapeutic course and two weeks therapeutic course of Ilaprazole and Bismuth potassium citrate combined with two kinds of antibiotics in the treatment of Helicobacter pylori (Hp)related chronic gastritis.Methods According to random number table method,156 patients with Hp related chronic gastritis in our hospital from January 2013 to June 2015 were selected and randomly divided into group A(n=78)and group B(n=78).All patients were treated with Ilaprazole 5 mg,Bismuth potassium citrate 0.6 g,Amoxicillin 1.0 g and Levofloxacin 0.2 g,2 times a day.Group A and group B was treated with the drugs for one week and two weeks respectively.The clinical effect,Hp eradication rate and adverse reactions between two groups were compared.Results The total effective rate of group A and group B was 93.6%and 94.9%respectively,there was no significant difference between two groups(P＞0.05).Hp eradication rate of group B(89.7%)was obviously higher than that of group A(75.6%)，the difference was statistically significant(P＜0.05).Incidence rate of adverse reactions in group A and group B was 6.4%and 9.0%respectively, there was no significant difference between two groups(P＞0.05).Conclusion The cure rate and Hp eradication rate of two weeks therapeutic course of Ilaprazole and Bismuth potassium citrate combined with two kinds of antibiotics in the treatment of Hp related chronic gastritis were obviously better than one week therapeutic course,and their adverse reactions is similar.

Key words： Helicobacter pylori Eradication therapy Combined therapy Chronic gastritis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Lan-min
	SHI Zhen-dong

Cite this article:

ZHAO Lan-min,SHI Zhen-dong. Effects comparison of different therapeutic course of Ilaprazole,bismuth and antibiotics in the treatment of Helicobacter pylori related chronic gastritis[J]. 中国当代医药, 2017, 24(3): 45-47.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I3/45

[1]	Malfertheiner P，Megraud F，OMorain CA，et al.Management of helicobacter pylori infection-the maastrichtⅣ/florence consensus report[J].Gut，2012，61（5）：646-664.
[2]	刘文忠，谢勇，成虹，等.第四次全国幽门螺杆菌感染处理共识报告[J].中华消化杂志，2012，32（10）：655-661.
[3]	高文，成虹，胡伏莲，等.含艾普拉唑四联七天疗法根除幽门螺杆菌的全国多中心临床研究[J].中华医学杂志，2012，32（10）：2108-2112.
[4]	卫金歧，陈美竹，伍百贺，等.艾普拉唑7d三联疗法及10d序贯疗法根除幽门螺杆菌的临床疗效[J].中国临床药学杂志，2012，21（5）：280-283.
[5]	张明磊，关会霞，陈渝宁.沈阳地区幽门螺杆菌流行病学调查研究[J].中国民康医学，2013，22（6）：489-490.
[6]	葛均波，徐永健.内科学[M].8版.北京：人民卫生出版社，2013：364-367.
[7]	中国幽门螺杆菌科研协作组.中国自然人群幽门螺杆菌感染的流行病学调查[J].现代消化及介入诊疗，2010，5（15）：265-270.
[8]	丛云燕，黄雪平，陈美竹，等.艾普拉唑联合铋剂10天四联方案治疗HP感染慢性胃炎疗效观察[J].山东医药，2014，54（14）：45-47.
[9]	陈渭，赵善池，王平.大蒜素联合艾普拉唑治疗十二指肠溃疡110例[J].中国药业，2016，25（2）：114-116.
[10]	《医学论坛网》.质子泵抑制剂可增加肾脏疾病风险[J].现代医院，2016，16（1）：79.
[11]	周丽君，李敬来，张振清.新型质子泵抑制剂艾普拉唑的研究进展[J].医学综述，2012，18（10）：1550-1552.
[12]	李长龄.常用处方药物手册[M].北京：北京科学技术出版社，2012.
[13]	吴永城，曾繁之，吴兴强，等.艾普拉唑序贯疗法对消化性溃疡患者血清一氧化氮和白细胞介素-17表达的影响[J].广东医学，2015，36（9）：1430-1432.
[14]	朱志芬.艾普拉唑肠溶片治疗十二指肠溃疡的疗效和安全性分析[J].检验医学与临床，2014，11（10）：1383.
[15]	刘勤俭.艾普拉唑肠溶片治疗十二指肠溃疡的疗效和安全性[J].检验医学与临床，2014，11（12）：1701-1702.
[16]	苏连明，艾江，孔祥红.艾普拉唑、阿莫西林、左氧氟沙星三联疗法治疗幽门螺杆菌感染的临床观察[J].实用药物与临床，2013，16（1）：24-25.
[17]	杨丽，周东晓，陈光耀，等.质子泵抑制剂发生小肠细菌过生长的临床研究[J].中国现代医生，2016，54（14）：97-99.